The Best of AACR
-
Special forum features advice about how to best communicate vaccine safety and efficacy
AACR Immediate Past President Antoni Ribas, MD, PhD, FAACR, and Gilbert S. Omenn, MD, PhD, moderated a panel focused on COVID-19 vaccine confidence.
-
New approaches to modulating T cells explored during plenary session
(Clockwise, from top left) Sergio Quezada, PhD, Michel Sadelain, MD, PhD, Ignacio Melero. MD, PhD, and Anjana Rao, PhD, discussed approaches to developing new immunotherapies.
-
Plenary highlights critical cancer drivers and novel therapeutic opportunities
(Clockwise, from top left) Olufunmilayo I. Olopade, MD, FAACR, Tony Hunter, PhD, FAACR, Dennis J. Slamon, MD, PhD, FAACR, and William George Kaelin Jr., MD, FAACR, were the presenters.
-
Panel to discuss how precision medicine can move toward health equity
(Clockwise, from top left) Luis Carvajal-Carmona, PhD, Tiffany Wallace, PhD, Nicole Coggins, PhD, Nora M. Navone, MD, PhD, and Kevin L. Gardner, PhD, took part.
-
New Drugs on the Horizon sessions offer first disclosures of novel agents
Investigators in three related sessions shared details about 12 small molecules and biologics in or about to be tested in phase I clinical trials.
-
Presidential Address: Using the immune system to fight melanoma
Antoni Ribas, MD, PhD, FAACR, discussed how researchers are working to change the treatment paradigm for patients with melanoma and reflected on his term as AACR President.
-
Opening Plenary highlights bench-to-bedside aspects of research and clinical treatment
Presenters were (clockwise, from top left): Zhijan Chen, PhD, Mark Dawson, MD, PhD, Melissa Davis, PhD, Karen Vousden, PhD, FAACR, Matthew Vander Heiden, MD, PhD, and Jonathan Weissman, PhD.
-
Clinical Trials Plenary features promising data on targeted therapies for solid tumors
(Clockwise, top left) Lipika Goyal, MD, Vivek Subbiah, MD, Jeffrey Goh, MBBS, and Jermaine Coward, MBBS, PhD, presented during the Annual Meeting’s last Clinical Trials Plenary session.
-
Plenary explores chromosomal instability’s role in cancer treatment
(Clockwise, top left) Samuel F. Bakhoum, MD, PhD, Karlene A. Cimprich, PhD, Stephen P. Jackson, PhD, and David Pellman, PhD, discussed its viability as a novel therapy target.
-
First Clinical Trials Plenary features practice-changing data from phase III trials
Updates on phase III trials came from (clockwise, top left) Matthew J. Matasar, MD, Jessica Hassel, MD, Patrick M. Forde, MBBCh, and Georgina V. Long, PhD, MBBS.